Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
1
Hyogo Prefectural Tamba Medical Center, Department of Internal Medicine, 2002-7 Iso, Hikami-cho, Tamba 669-3495, Japan
2
Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, 2-1-5 Arata-cho, Hyogo-ku, Kobe 652-0032, Japan
3
Hyogo Prefectural Harima-Himeji General Medical Center, Department of General Internal Medicine, 3-264 Kamiya-cho, Himeji 670-8560, Japan
4
Division of Community Medicine and Medical Education, Kobe University Graduate School of Medicine, 2-1-5 Arata-cho, Hyogo-ku, Kobe 652-0032, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Giuseppe La Torre
Vaccines 2022, 10(8), 1232; https://doi.org/10.3390/vaccines10081232
Received: 24 June 2022
/
Revised: 20 July 2022
/
Accepted: 26 July 2022
/
Published: 31 July 2022
(This article belongs to the Special Issue Vaccination Related Adverse Reaction)
This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using questionnaires. The main factors were age (<40, 40–59, and >60 years), sex, underlying disease, and first-dose adverse reaction. The primary outcomes were incidence of local and systemic adverse reactions (ARs) attributable to the vaccine. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Among 671 participants, 90% experienced local or systemic ARs. An AR to the first dose was associated with a significantly increased risk of an AR to the second dose (OR: 49.63, 95% CI: 21.96–112.16). ARs were less common among men than among women (OR: 0.36, 95% CI: 0.17–0.76). Local ARs were less common among those aged 60 years or older (OR: 0.35, 95% CI: 0.18–0.66), whereas systemic ARs were more common among those aged under 40 years. Information on ARs to the first dose is important for healthcare providers and recipients when making vaccination decisions.
View Full-Text
Keywords:
COVID-19 vaccine; adverse reactions; first dose; second dose
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Goda, K.; Kenzaka, T.; Yahata, S.; Okayama, M.; Nishisaki, H. Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine. Vaccines 2022, 10, 1232. https://doi.org/10.3390/vaccines10081232
AMA Style
Goda K, Kenzaka T, Yahata S, Okayama M, Nishisaki H. Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine. Vaccines. 2022; 10(8):1232. https://doi.org/10.3390/vaccines10081232
Chicago/Turabian StyleGoda, Ken, Tsuneaki Kenzaka, Shinsuke Yahata, Masanobu Okayama, and Hogara Nishisaki. 2022. "Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine" Vaccines 10, no. 8: 1232. https://doi.org/10.3390/vaccines10081232
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
